+54.4%
GSK vs NVDX
+815.5%
-761.1%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | NVDX | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | -1.9% | +2.1% | +0.2% |
| 7D | -3.6% | -0.9% | -2.7% | -3.6% |
| 30D | -5.9% | +3.0% | -8.9% | -5.8% |
| 3M | -4.3% | +6.8% | -11.0% | -4.0% |
| 6M | -10.8% | +28.6% | -39.4% | -10.4% |
| YTD | +1.8% | +17.0% | -15.2% | +2.2% |
| 1Y | +23.5% | +27.0% | -3.5% | +24.2% |
| All | +54.4% | +815.5% | -761.1% | +59.0% |
Cumulative growth
Daily Returns
Daily percentage return beside NVDX.
Daily Out/Under-Performance
Portfolio return minus NVDX return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × NVDX return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded NVDX wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling